liraglutide

Generic Name: liraglutide

Brand Name: Saxenda

Manufacturer: Novo Nordisk Canada Inc.

Therapeutic Area: Chronic weight management in adults

Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: ≥30 kg/m2 or greater (obese), or ≥27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

Manufacturer Requested Reimbursement Criteria¹: An adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients who have been diagnosed with: Obesity (BMI ≥30 kg/m2) AND prediabetes, or Overweight (BMI ≥27 kg/m2 and ≥30 kg/m2) with one or more weight-related comorbidity AND prediabetes.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.